Compass Therapeutics shares fall after disappointing cancer drug trial results

Grafa04-01

Shares of Compass Therapeutics (NASDAQ:CMPX) plummeted 14.5% to $1.62 on Tuesday following the release of underwhelming data from a clinical trial of its experimental biliary tract cancer drug, tovecimig.

The drug, when combined with chemotherapy, achieved an overall response rate (ORR) of 17.1% in patients, a notable improvement over the 5.3% ORR seen in patients receiving chemotherapy alone.

ORR measures the percentage of patients whose tumors shrink or disappear over a set period.

Despite the improvement, the results fell short of expectations.

Brokerage Leerink Partners noted that the 17.1% response rate was lower than anticipated and below the efficacy observed in earlier trials of tovecimig.

The brokerage also highlighted that competing treatments, such as AstraZeneca’s Enhertu (NASDAQ:AZN) and Incyte’s Pemazyre (NASDAQ:INCY), have demonstrated superior response rates in similar patient populations, putting additional pressure on Compass Therapeutics’ stock.

The disappointing data overshadowed the company’s year-to-date performance, with CMPX shares still up 31% in 2025, including session moves.

 

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment